CD276 and osteosarcoma: Furthermore, co-expressing a chemokine receptor (CXCR2) with the B7-H3 CAR construct significantly enhanced the anti-tumor activity of canine CAR-T cells, suggesting a potential strategy to improve CAR-T cell efficacy in osteosarcoma treatment (69).